RIG-I RNA激素激活免疫刺激性巨细胞,以增强对质母细胞瘤的检查点免疫疗法
bioRxiv : the preprint server for biology
|January 16, 2026
概括
像SLR14这样的网红酸诱导基因I (RIG-I) 激动剂可以在质母细胞瘤 (GBM) 中重新编程瘤相关的巨细胞 (TAM). 这种方法增强了抗瘤免疫力,并提高了这种侵袭性脑癌的治疗疗效.
科学领域:
- 神经瘤学神经瘤学
- 免疫学 免疫学 免疫学
- 分子生物学分子生物学
背景情况:
- 质母细胞瘤 (GBM) 是一种具有不良预后的侵袭性脑瘤.
- GBM瘤微环境抑制了抗瘤免疫力.
- 目前针对GBM的治疗方法的疗效有限.
研究的目的:
- 调查视网膜酸诱导基因I (RIG-I) 激动剂在治疗GBM中的潜力.
- 探索瘤相关巨细胞 (TAMs) 在GBM免疫治疗中的作用.
- 评估干环RNA14 (SLR14) 作为RIG-I激动剂的疗效.
主要方法:
- 在成年GBM患者数据集的in silico分析.
- 用SLR14治疗GBM的综合性小鼠模型.
- 评估巨细胞再极化和免疫细胞激活.
- 评估SLR14与化疗,放射疗法和免疫疗法的结合.
主要成果:
- 在TAM中RIG-I表达与GBM患者的存活率呈正相关.
- 内注射SLR14增强了现有的GBM治疗的疗效.
- SLR14激活了TAMs和原始的细胞毒性CD8+T淋巴细胞和NK细胞.
- RIG-I+巨被确定为SLR14抗GBM效应的关键调解者.
结论:
- RIG-I激动剂刺激为GBM治疗提供了一个新的策略.
- 通过RIG-I激活重新极化TAM可以克服GBM诱导的免疫抑制.
- SLR14显示出作为一种针对质母细胞瘤的免疫治疗剂的显著潜力.
相关概念视频
Experimental RNAi
7.3K
RNA interference (RNAi) is a cellular mechanism that inhibits gene expression by suppressing its transcription or activating the RNA degradation process. The mechanism was discovered by Andrew Fire and Craig Mello in 1998 in plants. Today, it is observed in almost all eukaryotes, including protozoa, flies, nematodes, insects, parasites, and mammals. This precise cellular mechanism of gene silencing has been developed into a technique that provides an efficient way to identify and determine the...
7.3K
Tumor Immunotherapy
1.8K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
1.8K
PI3K/mTOR/AKT Signaling Pathway
5.4K
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...
5.4K
mTOR Signaling and Cancer Progression
4.6K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
4.6K
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
493
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
493
RNA Interference
27.8K
RNA interference (RNAi) is a process in which a small non-coding RNA molecule blocks the post-transcriptional expression of a gene by binding to its messenger RNA (mRNA) and preventing the protein from being translated.
This process occurs naturally in cells, often through the activity of genomically-encoded microRNAs. Researchers can take advantage of this mechanism by introducing synthetic RNAs to deactivate specific genes for research or therapeutic purposes. For example, RNAi could be used...
This process occurs naturally in cells, often through the activity of genomically-encoded microRNAs. Researchers can take advantage of this mechanism by introducing synthetic RNAs to deactivate specific genes for research or therapeutic purposes. For example, RNAi could be used...
27.8K


